News

Boehringer Ingelheim GmbH won approval in the US for its drug to treat a challenging form of lung cancer, offering a growth avenue for the privately-held German pharmaceuticals company.
In results from a Phase Ib study, Hernexeos showed a 75 percent response rate and more than half of patients responded for at least six months.
In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they don't receive federal funding connected to the mRNA research cuts announced ...
Richard Childress Racing in the NASCAR Cup Series at Watkins Glen International… The NASCAR Cup Series returns to Watkins Glen International this weekend for the Go Bowling at The Glen, marking the ...
So Sir Pascal may seem an unlikely ally of Donald Trump, who as America’s president has slashed public spending on scientific ...